Core Viewpoint - ResMed Inc. has demonstrated strong momentum with a 37.8% increase in share price over the past year, outperforming the industry growth of 10.7% and the S&P 500's 26.2% increase, indicating solid investment potential for the company [1]. Company Overview - ResMed designs, manufactures, and distributes generators, masks, and related accessories for the treatment of sleep-disordered breathing and other respiratory disorders, operating under two segments: Sleep and Respiratory Care and Software-as-a-Service (SaaS) [2][3]. Growth Factors - The upward trend in ResMed's share price is driven by robust mask sales, strong respiratory care product performance, and a focus on international expansion, supported by a solid fiscal first-quarter performance [4]. - Investor optimism is bolstered by the launch of new patient-centric products, including the AirTouch N30i fabric mask, enhancing the therapy journey for sleep apnea patients [5]. - ResMed reported impressive fiscal first-quarter results, with significant year-over-year revenue growth across all product and geographic categories, aided by new patient activations and ongoing ReSupply programs [6]. Financial Performance - In the fiscal first quarter, ResMed achieved an adjusted gross profit of $724.9 million, a 17.5% year-over-year increase, with gross margin improving by 324 basis points to 59.2% [7]. - Adjusted operating income rose to $406.4 million, reflecting a 27.7% increase from the previous year, with the adjusted operating margin expanding by 431 basis points to 33.2% [7]. Future Estimates - ResMed's earnings per share (EPS) for fiscal 2025 are projected to grow by 21.1% to $9.35, with revenues expected to rise by 8.9% to $5.10 billion year-over-year [10].

Core Insights - The article discusses the Zacks Style Scores, which are designed to help investors identify stocks with the best chances of outperforming the market over the next 30 days [7][11]. Group 1: Zacks Style Scores Overview - Each stock is rated from A to F based on value, growth, and momentum characteristics, with A being the highest rating [2]. - The Value Style Score focuses on identifying attractive and discounted stocks using various financial ratios like P/E and Price/Sales [3]. - The Growth Style Score evaluates a company's financial strength and future outlook, analyzing projected and historical earnings, sales, and cash flow [8]. - The Momentum Style Score helps investors capitalize on price trends by assessing factors like one-week price change and monthly earnings estimate changes [18]. Group 2: Zacks Rank and Performance - The Zacks Rank utilizes earnings estimate revisions to assist investors in building successful portfolios, with 1 (Strong Buy) stocks achieving an average annual return of +25.41% since 1988, significantly outperforming the S&P 500 [10][19]. - Stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B are recommended for maximizing investment success [20]. - ResMed, Inc. (RMD) is highlighted as a stock to watch, holding a 2 (Buy) rating and a VGM Score of A, indicating strong potential [22]. Group 3: ResMed (RMD) Specifics - ResMed has a Value Style Score of B, supported by a forward P/E ratio of 24.93, making it attractive to value investors [14]. - Recent analyst activity shows two upward revisions in earnings estimates for fiscal 2025, with the Zacks Consensus Estimate increasing by $0.13 to $9.35 per share [23]. - ResMed has an average earnings surprise of 6.4%, indicating a positive trend in earnings performance [23].

Core Insights - The FDA approved Eli Lilly's weight-loss drug Zepbound for treating moderate-to-severe obstructive sleep apnea in adults with obesity, raising concerns for companies like ResMed and Inspire Medical Systems that currently provide treatment devices [6][4] - ResMed's Chief Medical Officer indicated that weight-loss medications could be used alongside existing therapies, suggesting a potential shift in treatment approaches for sleep apnea [4][6] - Despite a recent decline in stock prices, ResMed shares have increased by approximately 33% this year, while Inspire Medical Systems shares have decreased by 9% in 2024 [6][4] Company Impact - ResMed's shares fell about 4% following the FDA's decision, but the company has seen significant growth in stock value this year [6][4] - Inspire Medical Systems experienced a 1.4% drop in shares, reflecting investor concerns about competition from new weight-loss drugs [6][4] - Analysts show mixed ratings for both companies, with ResMed receiving three "buy" and four "hold" ratings, while Inspire Medical Systems has seven "buy" and two "hold" ratings [6][4]

Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. But finding a great growth stock is not easy at all.That's because, these stocks usually carry above-average risk and volatility. In fact, betting on a stock for which the growth story is actually over or nearing its end could lead to significant loss.However, the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style Scores? ...

Investors interested in Medical - Products stocks are likely familiar with ResMed (RMD) and Insulet (PODD) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The proven Zacks Rank emphasizes companies with positive estimate revis ...

Dublin, Dec. 04, 2024 (GLOBE NEWSWIRE) -- The "Canada Sleep Apnea Devices Market, By Region, Competition, Forecast & Opportunities, 2019-2029F" report has been added to ResearchAndMarkets.com's offering.Canada Sleep Apnea Devices Market was valued at USD 338.54 Million in 2023 and is expected to reach USD 465.53 Million by 2029 with a CAGR of 5.41% The Canada Sleep Apnea Devices Market is being driven by several key factors. The increasing prevalence of sleep apnea, fueled by rising obesity rates and an ag ...

Investors looking for stocks in the Medical - Products sector might want to consider either ResMed (RMD) or LeMaitre Vascular (LMAT) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies with positive earnings estima ...

Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a growth stock that can live up to its true potential can be a tough task.By their very nature, these stocks carry above-average risk and volatility. Moreover, if a company's growth story is over or nearing its end, betting on it could lead to significant loss.However, the task of finding cutting-edge growth stocks is mad ...

ResMed Inc.’s (RMD) growth in the first quarter of fiscal 2025 can be attributed to the robust performance of its Mask business. Its Device sales continue to drive overall revenue growth, driven by the combined availability of Airsense10 and Airsense11. The company’s investment in newer-to-market technologies within its Respiratory Care product space looks encouraging. However, the increasing debt burden on ResMed’s operations remains a concern.  In the past year, shares of this Zacks Rank #1 (Strong Buy) c ...